Holen Sie sich die Stockscreener-App
166.28
0.78%
1.29
Handel nachbörslich:
166.27
-0.010
-0.01%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ABBV?
Forum
Prognose
Dividendenhistorie
Schlusskurs vom Vortag:
$164.99
Offen:
$165.62
24-Stunden-Volumen:
6.73M
Relative Volume:
1.37
Marktkapitalisierung:
$293.80B
Einnahmen:
$55.53B
Nettoeinkommen (Verlust:
$5.12B
KGV:
45.56
EPS:
3.65
Netto-Cashflow:
$15.62B
1W Leistung:
-4.67%
1M Leistung:
-11.96%
6M Leistung:
-0.08%
1J Leistung:
+20.23%
1-Tages-Spanne:
$164.80
$166.74
1-Wochen-Bereich:
$164.72
$176.63
52-Wochen-Spanne:
$137.14
$207.32
Abbvie Inc Stock (ABBV) Company Profile
Firmenname
Abbvie Inc
Sektor
Telefon
(847) 932-7900
Adresse
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Vergleichen Sie ABBV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| ABBV | 166.28 | 293.80B | 55.53B | 5.12B | 15.62B | 3.65 |
| LLY | 727.20 | 683.37B | 40.86B | 8.37B | -2.28B | 5.4193 |
| NVO | 99.81 | 446.14B | 39.36B | 13.79B | 9.83B | 2.4077 |
| JNJ | 154.77 | 353.35B | 87.70B | 14.68B | 19.03B | 13.47 |
| MRK | 96.56 | 242.49B | 63.17B | 12.15B | 14.84B | 1.80 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-06-05 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-05-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-01-29 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | Herabstufung | HSBC Securities | Buy → Hold |
| 2023-12-11 | Hochstufung | Goldman | Neutral → Buy |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-10-30 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-09-29 | Eingeleitet | Raymond James | Outperform |
| 2023-07-25 | Eingeleitet | William Blair | Mkt Perform |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-04-05 | Herabstufung | Argus | Buy → Hold |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2023-02-22 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | Hochstufung | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-11-08 | Herabstufung | Societe Generale | Buy → Hold |
| 2022-08-01 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Underperform |
| 2022-05-06 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-02-28 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-03 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-03 | Bestätigt | Barclays | Equal Weight |
| 2022-02-03 | Bestätigt | BofA Securities | Neutral |
| 2022-02-03 | Bestätigt | Goldman | Neutral |
| 2022-01-13 | Eingeleitet | Redburn | Buy |
| 2022-01-12 | Bestätigt | BMO Capital Markets | Outperform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Overweight |
| 2021-11-23 | Hochstufung | Societe Generale | Hold → Buy |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2020-11-10 | Fortgesetzt | Bernstein | Outperform |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-06-23 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | Hochstufung | Argus | Hold → Buy |
| 2020-05-18 | Fortgesetzt | BofA/Merrill | Neutral |
| 2020-05-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-05-11 | Fortgesetzt | Morgan Stanley | Overweight |
| 2020-04-20 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | Herabstufung | Societe Generale | Buy → Hold |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | Bestätigt | Cowen | Outperform |
| 2019-09-26 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-08-20 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | Eingeleitet | Goldman | Neutral |
| 2019-04-29 | Hochstufung | BMO Capital Markets | Underperform → Market Perform |
Alle ansehen
Abbvie Inc Aktie (ABBV) Neueste Nachrichten
AbbVie snaps eight straight sessions of losses - Seeking Alpha
AbbVie (NYSE:ABBV) Trading Up 0.2%Time to Buy? - MarketBeat
Mawer Investment Management Ltd. Sells 14,746 Shares of AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie's Ovarian Cancer Drug Elahere Gets Approval in Europe - Yahoo Finance
Allergan Aesthetics Offers Free Business Education Courses Online to Support Growing Practices with Allergan Aesthetics Products - AbbVie
Allergan Aesthetics Launches Free Business Training Platform for Healthcare Practices | ABBV Stock News - StockTitan
GLOBALT Investments LLC GA Invests $3.78 Million in AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie Inc. (NYSE:ABBV) Shares Bought by Richard C. Young & CO. LTD. - MarketBeat
Aldeyra's Dry Eye Drug Gets FDA Review, Expands $400M AbbVie Partnership Deal | ALDX Stock News - StockTitan
Aljian Capital Management LLC Invests $1.33 Million in AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie Inc. (NYSE:ABBV) Shares Sold by MAI Capital Management - MarketBeat
AbbVie Inc. (NYSE:ABBV) Shares Sold by AMG National Trust Bank - MarketBeat
AbbVie bags EU nod for key drug from ImmunoGen takeover - pharmaphorum
AbbVie Gets European OK of Elahere in Platinum-Resistant Ovarian Cancer - MarketWatch
AbbVie’s Elahere wins European approval for certain ovarian cancers - Pharmaceutical Technology
AbbVie Receives European Commission Approval of ELAHERE® (mirvetuximab soravtansine) for the Treatment of Platinum-Resistant Ovarian Cancer - PR Newswire
AbbVie's (NYSE:ABBV) Shareholders Will Receive A Bigger Dividend Than Last Year - Yahoo Finance
Atlanta Consulting Group Advisors LLC Acquires Shares of 5,060 AbbVie Inc. (NYSE:ABBV) - MarketBeat
Sawgrass Asset Management LLC Has $13.61 Million Position in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Mutual of America Capital Management LLC Has $46.17 Million Stake in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Why AbbVie’s (ABBV) Drug Setback Creates A Prime Buy-The-Dip Moment - MSN
Natixis Advisors LLC Has $239.62 Million Stock Position in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Mizuho Securities USA LLC Reduces Position in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Mizuho Markets Americas LLC Decreases Stock Holdings in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Dividend King AbbVie Just Paid Investors: Here's How Much They Got - 24/7 Wall St.
Kentucky Retirement Systems Insurance Trust Fund Has $10.33 Million Stock Holdings in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Kentucky Retirement Systems Sells 10,016 Shares of AbbVie Inc. (NYSE:ABBV) - MarketBeat
Ipswich Investment Management Co. Inc. Sells 19,650 Shares of AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie Inc. (NYSE:ABBV) Shares Sold by Coastline Trust Co - MarketBeat
Wolfe Research Initiates Coverage of AbbVie (ABBV) with Outperform Recommendation - Nasdaq
AbbVie Inc. stock underperforms Friday when compared to competitors - MarketWatch
AbbVie (NYSE:ABBV) Shares Down 1.7%Should You Sell? - MarketBeat
AbbVie Stock Falls 11% In A Month: Should You Buy The Dip? - Barchart
AbbVie Stock Falls 11% in a Month: Should You Buy the Dip? - MSN
Simplify Asset Management Inc. Takes Position in AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie Inc. (NYSE:ABBV) Shares Sold by Empowered Funds LLC - MarketBeat
AbbVie, Bitcoin And An Energy Stock On CNBC's 'Final Trades' - Benzinga
Dearborn Partners LLC Has $42.34 Million Stock Position in AbbVie Inc. (NYSE:ABBV) - MarketBeat
CIBC Asset Management Inc Grows Stock Holdings in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Intellectus Partners LLC Decreases Stock Position in AbbVie Inc. (NYSE:ABBV) - MarketBeat
OneDigital Investment Advisors LLC Decreases Position in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Got $1,500 to Invest? AbbVie Just Proved the Bull Thesis for Its Stock - MSN
Protein Therapeutics Market Size to be Worth USD 549.4 billion by 2031, at a CAGR of 6.3% | Transparency Market Research, Inc. - GlobeNewswire Inc.
AbbVie Target of Unusually Large Options Trading (NYSE:ABBV) - MarketBeat
AbbVie Inc. stock outperforms competitors despite losses on the day - MarketWatch
AbbVie shares trade in the red for seventh straight session (NYSE:ABBV) - Seeking Alpha
ABBV: 3 Dividend Powerhouses Yielding Over 3% to Consider - StockNews.com
AbbVie Inc. (NYSE:ABBV) Shares Sold by ING Groep NV - MarketBeat
AbbVie (NYSE:ABBV) Trading Down 0.5% on Analyst Downgrade - MarketBeat
Tokio Marine Asset Management Co. Ltd. Purchases 3,304 Shares of AbbVie Inc. (NYSE:ABBV) - MarketBeat
William Blair Issues Positive Outlook for AbbVie Earnings - MarketBeat
Finanzdaten der Abbvie Inc-Aktie (ABBV)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.26%
0.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):